Conference Reports for NATAP

Back

IDSA Conference Infectious Disease Society San Diego, CA, Oct 7, 2007     Safety and tolerability of KP-1461 in phase 1, dose-ranging study in highly ART experienced HIV infected persons - (10/11/07)   48-Week Safety and Efficacy of Maraviroc in Combination with Optimized Background Therapy (OBT) for the Treatment of Antiretroviral-Experienced Patients Infected with Dual/Mixed-Tropic HIV-1 - (10/9/07)   Switching from Lopinavir/Ritonavir (LPV/r) Soft Gel Capsule (SGC) to Tablet Formulation improves Tolerability in Indigent AIDS Clinic - (10/9/07)   HIV & Aging: Overweight & Hypertension Increasing - (10/9/07)   TMC125 safety and tolerability: 24-week results of the pooled DUET-1 and -2 trials - (10/9/07)   Pooled 24-week results of DUET-1 and -2: efficacy of TMC125 in treatment-experienced HIV-1-infected patients - (10/9/07)   Influence of Baseline Factors on Virologic Response to Darunavir/Ritonavir (DRV/r) vs Lopinavir/r (LPV/r): Week 48 Outcome in TITAN - (10/9/07)